What Is the Highest Dose of Mounjaro? What the Label Says

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This guide lives in the PlexusDx Education Hub, where we unpack GLP-1 science, weight-management protocols, and the genetic factors behind metabolic decisions. Open the Education Hub

Why this is one of the most common searches

Questions about the highest Mounjaro dose rank among the most frequent in GLP-1 patient education, usually asked by someone approaching that step of the titration schedule. This article reports what the FDA-approved label describes, what patients typically experience, and where the top of the ladder sits, without providing prescribing or titration direction. Deciding your dose is your prescribing provider's role. Open the Education Hub for related guides.

Where the dose fits in the schedule

Tirzepatide, the active ingredient in Mounjaro, is titrated per the FDA-approved label starting at 2.5 mg weekly and moving through 5, 7.5, 10, 12.5, and 15 mg at minimum intervals. The highest labeled step sits at the top of that ladder. Where your specific dose falls is guided by your prescribing provider based on tolerability and clinical response, not by a fixed timeline anyone can apply to themselves.

What patients commonly report at each step

Gastrointestinal symptoms, including nausea, mild vomiting, and transient constipation or diarrhea, are the experiences most commonly reported during any dose step, and they tend to be most pronounced in the first few weeks after moving to a new dose. Appetite suppression, early satiety, and changes in meal portions are also frequently reported. These are individual experiences, and clinical outcomes vary widely from person to person.

When the next titration step happens

Titration intervals are specified in the product's FDA label, typically at least four weeks between steps, and are modified by the prescribing provider based on how a patient tolerates each dose and responds clinically. If gastrointestinal symptoms are significant, a provider may extend time at the current dose. If a dose is well tolerated but clinical goals are not yet met, the provider may advance per the label.

Side effects to watch for at any step

All FDA-approved GLP-1 receptor agonists and GIP/GLP-1 dual agonists carry the class boxed warning for thyroid C-cell tumor risk observed in rodent studies. Contact a provider for severe or persistent abdominal pain, which may signal pancreatitis, right-upper-quadrant pain with fever, which may signal gallbladder disease, persistent vomiting with dehydration, signs of hypoglycemia, or any allergic reaction symptom. Severe symptoms warrant urgent or emergency care.

Why the ladder is climbed gradually

The stepwise structure of the titration schedule is deliberate. Starting low and advancing at minimum intervals gives the body time to adjust and helps limit the gastrointestinal symptoms that tend to peak right after a dose change. That is why the highest labeled step is not a starting point and not a goal to rush toward, but the top of a ladder that many patients may never need to reach. Some people find that a lower step meets their clinical goals and stay there as a maintenance dose, while others move upward under provider guidance. The pace is individualized, shaped by tolerability and response, and any decision to hold, extend, or advance belongs to the prescriber. Chasing the top step on your own would ignore the very reason the schedule exists, which is to balance benefit against tolerability at each stage.

The biology beneath every step

Genetics shapes the baseline that any dose acts on. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights, including variants in FTO, GLP1R, MC4R, and TCF7L2 that influence appetite regulation and energy balance. It does not predict your response to any dose of any medication; it offers pathway-level context that applies at every step of the ladder. PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols.

Frequently Asked Questions

What is the top labeled Mounjaro dose?

Tirzepatide is titrated per the FDA-approved label from 2.5 mg weekly upward through 5, 7.5, 10, 12.5, and 15 mg at minimum intervals, with the highest step at the top of that ladder. Where your dose fits is guided by your prescribing provider based on tolerability and clinical response, not a self-set schedule.

How long do people stay on a given dose?

Titration intervals are specified in the FDA-approved label, typically a minimum of four weeks between steps, and are modified by the prescribing provider based on tolerability and response. Some patients remain at one dose long-term as a maintenance dose, while others titrate upward according to the labeled schedule under provider guidance.

What symptoms should prompt a call to my provider?

Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation are most common at any step. Contact your provider for severe abdominal pain, persistent vomiting with dehydration, right-upper-quadrant pain with fever, or any allergic reaction symptom. All GLP-1 pathway compounds carry the class boxed warning for thyroid C-cell tumor risk.

Does genetics predict my response at higher doses?

No. The Precision Peptide Genetic Test does not predict response to any specific dose of any specific medication. It analyzes pathway-level variants in FTO and MC4R, and TCF7L2 that shape baseline energy-balance biology, offering upstream context that applies across every step of the titration schedule.

Keep reading across the PlexusDx Education Hub for more evidence-based GLP-1 and metabolic health explainers. Return to the Education Hub

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.